che-13 Antibody

Here’s a structured FAQ for researchers working with CHE-13 antibody in academic contexts, based on experimental design and data analysis challenges:

What experimental designs resolve contradictory results in CHE-13’s role in IFT complex assembly?

Advanced strategy:

How to optimize CHE-13 antibody concentration for tissue-specific staining?

Titration protocol:

• Test 1:100–1:1,000 dilutions in fixation-dependent buffers (e.g., methanol vs. paraformaldehyde) .

• Use knockout validation: Compare staining intensity in wild-type and che-13(−) tissues .

• Quantify signal-to-noise ratios using imaging software (e.g., ImageJ).

What controls are critical when studying CHE-13’s role in cilia-related developmental defects?

Essential controls:

• Genetic: Include daf-19(−) mutants (lacking cilia transcription factor) to distinguish CHE-13-specific effects .

• Technical: Parallel staining with anti-α-tubulin (cilia marker) and DAPI (nuclear counterstain) .

• Phenotypic: Monitor chemotaxis defects (e.g., NaCl avoidance) to link molecular findings to organismal function .

How to interpret partial colocalization of CHE-13 with other IFT-B proteins?

Analytical framework:

What statistical methods address variability in CHE-13 antibody performance across labs?

Best practices:

• Use Cohen’s kappa coefficient to assess inter-lab staining reproducibility.

• Apply ANOVA with post-hoc tests for multi-condition cilia length measurements.

• Share raw imaging data via repositories (e.g., BioImage Archive) for independent validation.

How to integrate CHE-13 findings with broader ciliopathy research?

Translational workflow:

• Compare CHE-13 localization patterns with human homolog ANPEP/CD13 .

• Use structural modeling to map conserved residues (e.g., RFX-binding domains regulated by DAF-19) .

• Cross-reference with ciliopathy databases (e.g., Ciliopathy Alliance) for phenotype-genotype correlations.

Key Data Table: CHE-13 Antibody Performance Metrics